López-Camacho, C. et al. (2020) Immunogenicity and efficacy of Zika virus Envelope Domain III in DNA, protein and ChAdOx1 adenoviral-vectored vaccines. Vaccines, 8(2), 307. (doi: 10.3390/vaccines8020307) (PMID:32560145)
|
Text
217948.pdf - Published Version Available under License Creative Commons Attribution. 2MB |
Abstract
The flavivirus envelope protein domain III (EDIII) was an effective immunogen against dengue virus (DENV) and other related flaviviruses. Whether this can be applied to the Zika virus (ZIKV) vaccinology remains an open question. Here, we tested the efficacy of ZIKV-EDIII against ZIKV infection, using several vaccine platforms that present the antigen in various ways. We provide data demonstrating that mice vaccinated with a ZIKV-EDIII as DNA or protein-based vaccines failed to raise fully neutralizing antibodies and did not control viremia, following a ZIKV challenge, despite eliciting robust antibody responses. Furthermore, we showed that ZIKV-EDIII encoded in replication-deficient Chimpanzee adenovirus (ChAdOx1-EDIII) elicited anti-ZIKV envelope antibodies in vaccinated mice but also provided limited protection against ZIKV in two physiologically different mouse challenge models. Taken together, our data indicate that contrary to what was shown for other flaviviruses like the dengue virus, which has close similarities with ZIKV-EDIII, this antigen might not be a suitable vaccine candidate for the correct induction of protective immune responses against ZIKV.
Item Type: | Articles |
---|---|
Additional Information: | This report is independent research funded by the UK Department of Health and Social Care through Innovate UK “New vaccines for global epidemics: development and manufacture” grant No. 972216 (ARS), and also funded from an ODA budget (Global Health (ODA), 16/107/05 - Design, development and GMP manufacture of a Zika vaccine) (AHP, ARS). The views expressed in this publication are those of the authors and not necessarily those of the Department of Health and Social Care. ARS is a Jenner Investigator and an Oxford Martin Fellow. AP is supported by the UK Medical Research Council. JM is supported by an MRC-Newton Fund grant, GRS is aWellcome Trust Senior Investigator. |
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | De Lorenzo, Dr Giuditta and Patel, Professor Arvind |
Creator Roles: | De Lorenzo, G.Conceptualization, Data curation, Investigation, Methodology, Supervision, Validation, Visualization, Writing – original draft, Writing – review and editing Patel, A.Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Writing – review and editing |
Authors: | López-Camacho, C., De Lorenzo, G., Slon-Campos, J. L., Dowall, S., Abbink, P., Larocca, R. A., Kim, Y. C., Poggianella, M., Graham, V., Findlay-Wilson, S., Rayner, E., Carmichael, J., Dejnirattisai, W., Boyd, M., Hewson, R., Mongkolsapaya, J., Screaton, G. R., Barouch, D. H., Burrone, O. R., Patel, A. H., and Reyes-Sandoval, A. |
College/School: | College of Medical Veterinary and Life Sciences > School of Infection & Immunity College of Medical Veterinary and Life Sciences > School of Infection & Immunity > Centre for Virus Research |
Journal Name: | Vaccines |
Publisher: | MDPI |
ISSN: | 2076-393X |
ISSN (Online): | 2076-393X |
Copyright Holders: | Copyright © 2020 The Authors |
First Published: | First published in Vaccines 8(2):307 |
Publisher Policy: | Reproduced under a Creative Commons License |
University Staff: Request a correction | Enlighten Editors: Update this record